Program
episalvan
Also written as “Oleogel-S10”, “AP-101” and “Oleogel-S10, non-adhesive wound dressing”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Epidermolysis Bullosa · Wounds and Injuries · Epidermolysis Bullosa Dystrophica · Burns, led by 2 companies.
Drug pageEpisalvan: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceuticiits history only | 81 open or running | phase 3since Jul 29, 2012 | Nov 5, 2008 | none ahead |
| AL-S Pharma | 20 open or running | phase 2since Sep 1, 2021 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AL-S Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 30, 2019First study: phase 1 study in Amyotrophic Lateral SclerosisFirst studyNCT03981536 · 18 enrolled · Canada
- Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisNCT05039099 · 73 enrolled · United States, Belgium, Canada and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 AL-S Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05039099Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more | 2 | Completed | Aug 13, 2025 | 73 |
| NCT03981536Amyotrophic Lateral Sclerosis · Canada | 1 | UNKNOWN | Nov 2, 2020 | 18 |
How it is read
Names in the registry
- “Oleogel-S10”, 4 entries
- “AP-101”, 2 entries
- “Oleogel-S10, non-adhesive wound dressing”, 2 entries
- “Oleogel-S10 ointment”, 1 entry
- “Oleogel-S10 100 mg/g”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 2 studies
- Epidermolysis Bullosa, 2 studies
- Wounds and Injuries, 2 studies
- Epidermolysis Bullosa Dystrophica, 1 study
- Burns, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.